BC Platforms secured $15 million Series C from IQVIA et all.
BC Platforms, an Espoo, Finland and Zurich, Switzerland-based provider of genomic data management and analytics, announced securing $15 million series C investment funding.
The deal was announced alongside a new commercial collaboration with IQVIA, which also led the equity funding, with Debiopharm Innovation Fund and Tesi, a Finnish venture capital and private equity company. As part of the collaboration, IQVIA and BC Platforms plan to launch new data driven technologies, integrating complex clinical and genomic data, to benefit transformational research.
The company will use the fundraising proceeds to expand its global network of clinical and genomics data, delivering novel automated solutions to pharmaceutical companies.
BC Platforms, founded in 1997 from an MIT Whitehead project spinoff and led by CEO Tero Silvola, developed a genomic data management platform that enables flexible data integration, secure analysis and interpretation of molecular and clinical information, providing powerful genomic data management and analysis solutions.
BC Platforms has global operations with its headquarters in Zurich, Switzerland, research and development in Espoo, Finland, and sales and marketing in London, Boston, Vancouver and Singapore. The company has established partnerships with approximately 100 enterprise level healthcare systems and biobanks globally in 25 countries.
Prior to this round, BC Platforms raised $10M in 2017.